Casirivimab and imdevimab (REGN-COV2), which is produced by Regeneron Pharmaceuticals, should be used for outpatient treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 88 pounds) as soon as possible after positive results of direct SARS-CoV-2 viral testing and within 10 days of symptom onset, and who are at high risk for progressing to severe COVID-19 and/or hospitalization. The dosage is 1200 mg of casirivimab and 1200 mg of imdevimab administered together as a single IV infusion over at least 20 minutes via pump or gravity. Patients should be monitored during infusion and for at least one hour after infusion is complete. Additional information can be found in the MAT assessment.

Download this resource